Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 10

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 10
---
omonas phage cocktail for acute ventilator-associated pneumonia
and severe infections due to multidrug-resistant P. aeruginosa.

Staphylococcus aureusPhage Product Candidate, AP-SA02

Clinical Development of AP-SA02 in Bacteremia: Completed Phase 1b/2a Study

In parallel to developing
novel phage therapeutics that target chronic bacterial infections, we have an acute bacterial infection clinical development plan focused
on S. aureusbacteremia, a difficult-to-treat and often life-threatening human infection that can result in high morbidity and
mortality and for which bacterial resistance to antibiotics is growing.

A key advantage of our
phage manufacturing expertise is the purity profiles of our phage products, including AP-SA02, our phage product candidate
for S. aureus; this has enabled us to pursue treatment of complicated S. aureus bacteremia, where
repetitive intravenous dosing is required. On June 15, 2020, we entered into an agreement (the “MTEC Agreement”)
with the Medical Technology Enterprise Consortium (“MTEC”), pursuant to which we received a $15.0 million award and
entered into a multi-year program administered by the U.S. Department of Defense (the “DoD”) through MTEC and managed by
the Naval Medical Research Command – Naval Advanced Medical Development with funding from the Defense Health Agency and Joint
Warfighter Medical Research Program. On September 29, 2022, the MTEC Agreement was modified to increase the total award by $1.3
million to $16.3 million and extend the term into the second half of 2024. On July 29, 2024, the MTEC Agreement was modified to
increase the total award by $5.3 million to $21.6 million and extend the term into the third quarter of 2025. On April 29, 2025, we received $4.65 million of additional non-dilutive award funding through MTEC, thereby increasing the total MTEC award to $26.2 million, and the MTEC Agreement was modified to extend the term to September 30, 2025. On July 2, 2025, the MTEC Agreement was modified to extend the term to March 31, 2026.We are using the award to partially fund a
Phase 1b/2a, multicenter, randomized, double-blind,